[ 52 Mn]Mn-BPPA-Trastuzumab: A Promising HER2-Specific PET Radiotracer
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c00344 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Ngô Minh Toàn und 13 weiteren Autor:innen. Beteiligte Einrichtung: Gyula Petrányi Doctoral School of Clinical Immunology and Allergology, Faculty of Medicine, University of Debrecen, Debrecen H-4032, Hungary. Hauptthemen laut MEDLINE: Manganese, Mice, SCID, Positron-Emission Tomography, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Nemzeti Kutat?si Fejleszt?si ?s Innov?ci?s Hivatal.
Abstract (Originalsprache)
This study aimed to develop a novel radiotracer using trastuzumab and the long-lived [52Mn]Mn isotope for HER2-targeted therapy selection and monitoring. A new Mn(II) chelator, BPPA, synthesized from a rigid bispyclen platform possessing a picolinate pendant arm, formed a stable and inert Mn(II) complex with favorable relaxation properties. BPPA was converted into a bifunctional chelator (BFC), conjugated to trastuzumab, and labeled with [52Mn]Mn isotope. In comparison to DOTA-GA-trastuzumab, the BPPA-trastuzumab conjugate exhibits a labeling efficiency with [52Mn]Mn approximately 2 orders of magnitude higher. In female CB17 SCID mice bearing 4T1 (HER2-) and MDA-MB-HER2+ (HER2+) xenografts, [52Mn]Mn-BPPA-trastuzumab demonstrated superior uptake in HER2+ cells on day 3, with a 3-4 fold difference observed on day 7. Overall, the hexadentate BPPA chelator proves to be exceptional in binding Mn(II). Upon coupling with trastuzumab as a BFC ligand, it becomes an excellent imaging probe for HER2-positive tumors. [52Mn]Mn-BPPA-trastuzumab enables an extended imaging time window and earlier detection of HER2-positive tumors with superior tumor-to-background contrast.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Gyula Petrányi Doctoral School of Clinical Immunology and Allergology, Faculty of Medicine, University of Debrecen, Debrecen H-4032, Hungary.
- Medical Imaging Clinic, Clinical Centre, University of Debrecen, Debrecen H-4032, Hungary.
- Scanomed Ltd., Debrecen H-4032, Hungary.
- Department of Physical Chemistry, Institute of Chemistry, Faculty of Science and Technology, University of Debrecen, Debrecen H-4032, Hungary.
- Doctoral School of Chemistry, Faculty of Science and Technology, University of Debrecen, Debrecen H-4032, Hungary.
ORCID-Profile: Ngô Minh Toàn
Förderung
- Nemzeti Kutat?si Fejleszt?si ?s Innov?ci?s Hivatal
Zitieren
APA
Toàn, N. M., Vágner, A., Nagy, G., Ország, G., Nagy, T., Csikos, C., Váradi, B., Sajtos, G. Z., Kapus, I., Szoboszlai, Z., Szikra, D., Trencsényi, G., Tircsó, G., & Garai, I. (2024). [ 52 Mn]Mn-BPPA-Trastuzumab: A Promising HER2-Specific PET Radiotracer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00344
Vancouver
Toàn NM, Vágner A, Nagy G, Ország G, Nagy T, Csikos C, et al. [ 52 Mn]Mn-BPPA-Trastuzumab: A Promising HER2-Specific PET Radiotracer. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00344
BibTeX
@article{Ton2024,
author = {Toàn, Ngô Minh and Vágner, Adrienn and Nagy, Gábor and Ország, Gábor and Nagy, Tamás and Csikos, Csaba and Váradi, Balázs and Sajtos, Gergő Zoltán and Kapus, István and Szoboszlai, Zoltán and Szikra, Dezső and Trencsényi, György and Tircsó, Gyula and Garai, Ildikó},
title = {[ 52 Mn]Mn-BPPA-Trastuzumab: A Promising HER2-Specific PET Radiotracer},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c00344}
}
EUVIMED